P
PharmaResearch Co Ltd
KOSDAQ:214450
PharmaResearch Co Ltd
KOSDAQ:214450
Price:
256 500
KRW
1.18%
Market Closed
Market Cap:
2.7T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
PharmaResearch Co Ltd
256500
+3000 (+1.18%)
| 52 Week Range |
89 100
259 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
PharmaResearch Co Ltd
Balance Sheet
Balance Sheet Decomposition
PharmaResearch Co Ltd
PharmaResearch Co Ltd
| Current Assets | 337.7B |
| Cash & Short-Term Investments | 216.4B |
| Receivables | 51.8B |
| Other Current Assets | 69.4B |
| Non-Current Assets | 303.1B |
| Long-Term Investments | 108.9B |
| PP&E | 146.1B |
| Intangibles | 32.9B |
| Other Non-Current Assets | 15.3B |
| Current Liabilities | 84.2B |
| Accounts Payable | 8.2B |
| Accrued Liabilities | 27.2B |
| Short-Term Debt | 250m |
| Other Current Liabilities | 48.6B |
| Non-Current Liabilities | 46.6B |
| Long-Term Debt | 8.9B |
| Other Non-Current Liabilities | 37.7B |
Balance Sheet
PharmaResearch Co Ltd
PharmaResearch Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
9 890
|
14 864
|
17 634
|
16 990
|
21 096
|
19 738
|
26 715
|
41 674
|
72 931
|
67 245
|
|
| Cash |
0
|
1
|
2
|
6
|
0
|
2
|
5
|
3
|
8
|
67 245
|
|
| Cash Equivalents |
9 890
|
14 863
|
17 632
|
16 984
|
21 096
|
19 736
|
26 710
|
41 672
|
72 923
|
0
|
|
| Short-Term Investments |
13
|
108 181
|
92 349
|
70 622
|
54 301
|
49 292
|
52 552
|
115 123
|
111 412
|
93 053
|
|
| Total Receivables |
6 255
|
5 850
|
10 782
|
18 358
|
17 243
|
20 589
|
26 351
|
30 510
|
36 415
|
36 330
|
|
| Accounts Receivables |
4 610
|
5 725
|
10 689
|
15 310
|
16 028
|
20 225
|
22 890
|
27 928
|
33 202
|
31 812
|
|
| Other Receivables |
1 645
|
125
|
93
|
3 048
|
1 215
|
364
|
3 461
|
2 582
|
3 213
|
4 519
|
|
| Inventory |
2 197
|
4 783
|
5 445
|
5 119
|
12 294
|
13 928
|
20 781
|
17 342
|
24 453
|
50 232
|
|
| Other Current Assets |
659
|
538
|
259
|
1 247
|
836
|
926
|
1 005
|
2 142
|
2 134
|
9 604
|
|
| Total Current Assets |
19 014
|
134 214
|
126 468
|
112 335
|
105 769
|
104 473
|
127 404
|
206 792
|
247 345
|
256 465
|
|
| PP&E Net |
21 023
|
20 396
|
20 771
|
27 179
|
66 064
|
73 886
|
94 046
|
109 481
|
117 960
|
123 061
|
|
| PP&E Gross |
21 023
|
20 396
|
20 771
|
27 179
|
66 064
|
73 886
|
94 046
|
109 481
|
117 960
|
123 061
|
|
| Accumulated Depreciation |
1 402
|
2 442
|
3 773
|
5 021
|
7 778
|
12 166
|
15 677
|
21 839
|
26 837
|
34 079
|
|
| Intangible Assets |
1 583
|
1 647
|
2 289
|
2 284
|
31 980
|
29 806
|
26 811
|
26 025
|
24 017
|
20 323
|
|
| Goodwill |
0
|
0
|
1 918
|
1 036
|
13 738
|
13 738
|
12 492
|
16 764
|
13 810
|
11 652
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
1 000
|
3 624
|
0
|
4 794
|
4 434
|
3 938
|
|
| Long-Term Investments |
2 471
|
12 905
|
27 652
|
45 048
|
37 150
|
40 552
|
54 395
|
58 268
|
59 361
|
112 777
|
|
| Other Long-Term Assets |
294
|
144
|
233
|
1 151
|
2 488
|
3 847
|
4 684
|
5 523
|
11 128
|
7 066
|
|
| Other Assets |
0
|
0
|
1 918
|
1 036
|
13 738
|
13 738
|
12 492
|
16 764
|
13 810
|
11 652
|
|
| Total Assets |
44 385
N/A
|
169 306
+281%
|
179 332
+6%
|
189 034
+5%
|
258 188
+37%
|
269 925
+5%
|
319 831
+18%
|
427 647
+34%
|
478 055
+12%
|
535 281
+12%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1 272
|
1 064
|
2 029
|
1 732
|
4 457
|
5 359
|
1 876
|
2 939
|
3 527
|
2 831
|
|
| Accrued Liabilities |
131
|
135
|
179
|
115
|
333
|
492
|
534
|
703
|
860
|
974
|
|
| Short-Term Debt |
2 500
|
0
|
0
|
0
|
0
|
0
|
15 000
|
15 800
|
15 550
|
400
|
|
| Current Portion of Long-Term Debt |
3 210
|
0
|
0
|
0
|
3 019
|
3 507
|
4 581
|
4 961
|
5 024
|
32 606
|
|
| Other Current Liabilities |
3 507
|
5 960
|
3 999
|
5 016
|
7 671
|
9 232
|
13 858
|
23 602
|
29 292
|
29 088
|
|
| Total Current Liabilities |
10 620
|
7 158
|
6 207
|
6 863
|
15 480
|
18 590
|
35 849
|
48 005
|
54 253
|
65 899
|
|
| Long-Term Debt |
8 997
|
5 401
|
0
|
0
|
17 343
|
17 435
|
12 829
|
44 850
|
46 194
|
1 301
|
|
| Deferred Income Tax |
0
|
0
|
114
|
0
|
6 061
|
5 404
|
4 746
|
4 514
|
3 741
|
2 794
|
|
| Minority Interest |
0
|
0
|
824
|
3 299
|
21 250
|
19 349
|
18 989
|
22 917
|
28 153
|
29 091
|
|
| Other Liabilities |
0
|
0
|
546
|
19
|
430
|
73
|
1 996
|
1 919
|
2 211
|
3 092
|
|
| Total Liabilities |
19 617
N/A
|
12 559
-36%
|
7 691
-39%
|
10 181
+32%
|
60 565
+495%
|
60 851
+0%
|
74 409
+22%
|
122 205
+64%
|
134 552
+10%
|
102 178
-24%
|
|
| Equity | |||||||||||
| Common Stock |
3 005
|
4 582
|
4 733
|
4 733
|
4 733
|
4 777
|
4 895
|
5 056
|
5 056
|
5 160
|
|
| Retained Earnings |
21 965
|
34 843
|
46 859
|
56 994
|
69 027
|
82 783
|
112 615
|
154 018
|
190 862
|
260 787
|
|
| Additional Paid In Capital |
0
|
116 629
|
121 893
|
121 893
|
122 113
|
124 366
|
131 120
|
150 127
|
155 297
|
172 641
|
|
| Unrealized Security Profit/Loss |
0
|
3
|
76
|
166
|
86
|
237
|
104
|
803
|
4 835
|
3 815
|
|
| Treasury Stock |
0
|
0
|
2 684
|
4 987
|
267
|
5 260
|
5 260
|
5 260
|
5 260
|
4 638
|
|
| Other Equity |
203
|
689
|
763
|
54
|
1 932
|
2 171
|
1 950
|
2 303
|
2 383
|
3 028
|
|
| Total Equity |
24 768
N/A
|
156 747
+533%
|
171 641
+10%
|
178 853
+4%
|
197 623
+10%
|
209 075
+6%
|
245 423
+17%
|
305 442
+24%
|
343 503
+12%
|
433 104
+26%
|
|
| Total Liabilities & Equity |
44 385
N/A
|
169 306
+281%
|
179 332
+6%
|
189 034
+5%
|
258 188
+37%
|
269 925
+5%
|
319 831
+18%
|
427 647
+34%
|
478 055
+12%
|
535 281
+12%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
6
|
9
|
9
|
9
|
9
|
9
|
10
|
10
|
10
|
10
|
|
| Preferred Shares Outstanding |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
